drugset / Trial / NCT02391545
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
RandomizedParallel-groupOpen-labelTreatment
Summary
A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.
Timeline
- Start
- 2014-12
- Primary completion
- 2017-01-17
- Completion
- 2017-05
Outcome
Outcome not reported
Stopped: “Sponsor is focusing on studies which can enable registration of duvelisib.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |